Dr. Ashley Byars of Royal Business Solutions Shares Insights on Empowering Young Entrepreneurs in HelloNation Magazine
BROWNSVILLE, Tenn., June 04, 2025 (GLOBE NEWSWIRE) -- How can we prepare today's youth to become tomorrow's innovators and leaders? Dr. Ashley Byars of Royal Business Solutions in Brownsville, Tennessee, explores this question by emphasizing the importance of youth entrepreneurship in an article for HelloNation Magazine. Her guidance highlights how early exposure, encouragement, and structured support can help young people see entrepreneurship as an achievable path, not a distant dream.
According to Byars, the foundation of entrepreneurship lies in confidence, not capital. Young individuals already possess essential traits such as curiosity, creativity, and determination. The challenge often lies in access to experiences that build on those traits. By supporting initiatives that teach entrepreneurship to youth through school programs, community workshops, or mentorship, adults can foster independence, initiative, and responsibility.
Byars notes that small-scale ventures, like selling handmade items or offering services, instill practical skills and confidence. These early business experiences teach budgeting, communication, and customer service, all while nurturing a problem-solving mindset. As she explains, guiding youth through the process of identifying needs and creating value empowers them to turn everyday challenges into innovative solutions.
In the article, Step Into Success: Empowering the Youth of America to Explore Entrepreneurship, Byars encourages a cultural shift that emphasizes entrepreneurial education programs and consistent mentorship as tools to help youth build resilient, purpose-driven futures.
About HelloNationHelloNation is a premier media platform that connects readers with trusted professionals and businesses across various industries. Through its innovative 'edvertising' approach that blends educational content and storytelling, HelloNation delivers expert-driven articles that inform, inspire, and empower. Covering topics from home improvement and health to business strategy and lifestyle, HelloNation highlights leaders making a meaningful impact in their communities.
Staff Writerinfo@hellonation.comwww.hellonation.comA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2968f4b9-c06a-4101-b54b-04c55fb7eddd
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Big Ass Fans Introduces Torrent™ – The Portable Misting Solution Conquering Heat in Complex Environments
Torrent's state-of-the-art design sets a new standard for unparalleled cooling endurance. Lexington, Kentucky, June 06, 2025 (GLOBE NEWSWIRE) -- New from Big Ass Fans, a Madison Air Company, Torrent™ is the ultimate portable cooling powerhouse for outdoor spaces, sporting events, and warehouses. With four wheels, 48-hour run time, and cooling capabilities by 25 °F, Torrent is an easy-to-use, rugged, AMCA-certified misting solution. For 25 years, Big Ass Fans has led the high-volume low-speed (HVLS) industry with premium, innovative products that provide best-in-class cooling comfort in complex environments. Torrent carries on this legacy. In a recent Big Ass Fans study, Torrent demonstrated dramatic cooling coverage while exhibiting unparalleled durability and endurance—making it a superior solution for rapid heat relief and field reliability. With an atomizing mister and 35-gallon water tank, this 30-inch fan provides continuous cooling comfort for up to four days so work shifts are not interrupted. Torrent's 25-degree cooling effect increases worker productivity up to 20%. Moreover, fewer cooling devices are needed to protect more people with an industry leading coverage area of 2,725 square feet. This ultimate cooling powerhouse with mobility indoors and out provides simple setup and maintenance with a 5-year warranty. 'Big Ass Fans strives to mitigate heat stress and provide industry-leading airflow. We enable employee well-being for increased productivity, performance and customer satisfaction for every product we bring to market,' said Leah Larson, the Chief Executive Officer at Big Ass Fans. 'Torrent is the bigger, bolder, longer-lasting cooler our customers asked for, and we're proud to deliver.' Torrent is available for purchase as of 4/22/2025. To learn more and to preview the product, please visit Torrent Portable Misting Fan. ## Big Ass FansBringing industry-leading airflow and energy savings to customers worldwide, Big Ass Fans exists to provide the best, most durable fans to fit any customer's needs. Big Ass Fans is guided by the high-volume, low-speed (HVLS) airflow concept to make spaces more comfortable and efficient. From factories to homes and everywhere in between, Big Ass fans deliver comfort, style and energy savings that make life and work more enjoyable. To learn more about Big Ass Fans visit About Madison AirMadison Air, one of the world's leading privately held companies, combines the innovation and nimble, responsive service of a startup with the sophistication and scale of a global enterprise. Madison Air's best-in-class portfolio of innovative brands make the world safer, healthier and more productive through the power of better air. Our purpose is rooted in the belief that whether it's protecting valuable data or equipment, optimizing crop quality and yield, or improving the productivity, health and retention of your workers, there's a direct correlation between air and outcomes. Please visit us at CONTACT: Michelle Moore Big Ass Fans 8592002750 in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL. In a recent Q&A hosted by Susan Thornton, CEO of the Cutaneous Lymphoma Foundation, a patient advocacy group, Dr. Kim shared her gratitude to clinical trial participants and emphasized the urgent need for safer, more effective therapies for CTCL. The conversation underscored the progress being made with HyBryte™, Soligenix's novel, non-mutagenic photodynamic therapy. 'We need new therapies and access to therapies [for patients],' said Dr. Kim, noting that CTCL is a chronic disease which means that therapies with possible side effects, such as the development of contact dermatitis, sun damage or skin cancer from phototherapy, can become a real issue for patients over time. 'There hasn't been an FDA-approved, new skin-directed therapy for over 10 years, so we really need new ones that are safe and hopefully safer [than the ones currently in use].' Clinical results from ongoing studies have been promising, with Dr. Kim noting that participants have experienced positive outcomes and that the therapy has been well tolerated, with no dropouts due to serious adverse events. "HyBryte™ has a unique mechanism of action, so it doesn't damage DNA, unlike phototherapy, so theoretically it's less mutagenic and there's less risk of skin cancer. It's not systemically absorbed, based on prior studies, and seems to be quite well tolerated in terms of its effects on the local skin area,' added Dr. Kim. As a professor of dermatology at the Hospital of the University of Pennsylvania and Director of the Penn Cutaneous Lymphoma Program, Dr. Kim is keen to continue her research into CTCL with colleagues and patients alike. 'There aren't that many clinical trials going on for early-stage disease,' Dr. Kim stated, adding she is very excited for what lies ahead now that open enrollment in HyBryte™ clinical trials is available. 'Hopefully we can get this over the finish line. We can't thank patients enough; it's so critical for getting new therapies approved.' To watch Dr. Kim's interview and learn more about the real-world clinical study of the treatment of Mycosis Fungoides with Synthetic Hypericin and Visible Light, please visit: About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer (SGX942), and in Behçet's Disease (SGX945). Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA). For further information regarding Soligenix, Inc., please visit the Company's website at and follow us on LinkedIn and Twitter at @Soligenix_Inc. This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma or any other studies (including the open-label, investigator-initiated study), there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA's concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Additionally, despite the biologic activity observed in aphthous ulcers induced by chemotherapy and radiation, there can be no assurance as to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events. Corporate Communications IBN Austin, Texas 512.354.7000 Office Editor@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Free eBook Offers Expert Tips on Creating Sustainable Kitchens and Baths
Green Builder Media offers trends and ideas to upgrade the most-used spaces in today's homes. Get Your Free Copy of Sustainable Kitchens and Baths Lake City, Colo., June 06, 2025 (GLOBE NEWSWIRE) -- As homeowners seek smarter, healthier, and greener living spaces, Green Builder Media is offering a powerful new resource to help industry professionals and consumers alike make the most of their kitchen and bath upgrades. 'Sustainable Kitchens and Baths: Updating the Most Used Spaces in Your Home for Smarter, Healthier, Greener Living' is a free downloadable eBook packed with practical strategies to reduce carbon emissions, optimize water use, increase energy efficiency, and enhance indoor air quality. Download the book here. From new construction to thoughtful retrofits, the eBook offers inspiration for builders, architects, designers, and homeowners who want their kitchens and baths to be both beautiful and climate-resilient. 'Whether it's embracing induction cooking or choosing cabinetry with low-emissions finishes, these high-use spaces present a huge opportunity for impact,' says Green Builder Media Associate Editor Michele Lerner. According to Green Builder Media's COGNITION Smart Data, nearly 50% of homeowners already use energy-efficient appliances, and more than 25% are interested in adopting induction cooking. A growing number are also exploring leak detection, greywater systems, and hot water recycling as part of a comprehensive water management approach. Inside the eBook: How builders and manufacturers are using recycled materials to create stunning designs The benefits of induction cooking and other cutting-edge appliances Tips for choosing healthy, low-VOC cabinets and finishes How smart water management can save money and protect your home High-performance remodeling strategies that increase comfort, efficiency, and value Download your free copy today and start transforming your kitchen and bath into spaces that truly reflect the future of sustainable living. About Green Builder Media Green Builder Media is North America's leading media company focused on green building and sustainable living content. With a comprehensive suite of content marketing, digital, social, and print media options, high-profile demonstration projects, market intelligence, data services, and live events, Green Builder Media offers a blend of visionary and practical information covering a broad spectrum of topics, including decarbonization, electrification, smart home technologies, energy efficiency, intelligent water, indoor air quality, resilient housing, renewables, and clean transportation. Attachment Get Your Free Copy of Sustainable Kitchens and Baths CONTACT: Cati O'Keefe Green Builder Media 513-532-0185 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
